Clinical Guidelines

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Share

  • 1

    MGUS is asymptomatic and can progress to multiple myeloma.

  • 2

    Risk stratification is crucial for determining management.

  • 3

    Ms. Jones presents with intermediate-risk MGUS.

  • 4

    Long-term monitoring is essential for MGUS.

  • 5

    Genetic markers influence progression risk.

  • 6

    Multidisciplinary approaches improve patient outcomes.

  • 7

    New models like PANGEA provide insights into cancer progression.

  • 8

    Education of healthcare providers on MGUS characteristics is needed.

Original Source(s)

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • by Kimberly Noonan, DNP, ANP-BC, AOCN, FAAN, Kevin Brigle, PhD, ANP, Charise Gleason, MSN, NP-C, AOCNP, Carrie Bellerive, BS, RN, BMTCN, Mary Steinbach, DNP, APRN, Deborah Doss, RN, OCN

  • March 4, 2026

Related Content

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

AML Complexity Uncovered: A Unified Whole Genome and Informatics Approach for High Resolution Disease Understanding

Standard-of-care (SOC) genomic testing in acute myeloid leukemia (AML) has historically resulted in fragmented, incomplete genomic profiles that mask clinically significant biology.

  • March 12, 2026

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...